JP2022520997A - イミプリドンを使用する方法 - Google Patents

イミプリドンを使用する方法 Download PDF

Info

Publication number
JP2022520997A
JP2022520997A JP2021549213A JP2021549213A JP2022520997A JP 2022520997 A JP2022520997 A JP 2022520997A JP 2021549213 A JP2021549213 A JP 2021549213A JP 2021549213 A JP2021549213 A JP 2021549213A JP 2022520997 A JP2022520997 A JP 2022520997A
Authority
JP
Japan
Prior art keywords
clpp
cancer
patient
cells
onc201
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549213A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020172485A5 (https=
JP2022520997A5 (https=
Inventor
マイケル アンドリーフ
丈 石澤
デイビッド シーマー
サラ ザラビ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2022520997A publication Critical patent/JP2022520997A/ja
Publication of JPWO2020172485A5 publication Critical patent/JPWO2020172485A5/ja
Publication of JP2022520997A5 publication Critical patent/JP2022520997A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2021549213A 2019-02-22 2020-02-21 イミプリドンを使用する方法 Pending JP2022520997A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962809140P 2019-02-22 2019-02-22
US62/809,140 2019-02-22
US201962908105P 2019-09-30 2019-09-30
US62/908,105 2019-09-30
PCT/US2020/019142 WO2020172485A1 (en) 2019-02-22 2020-02-21 Methods of using imipridones

Publications (3)

Publication Number Publication Date
JP2022520997A true JP2022520997A (ja) 2022-04-04
JPWO2020172485A5 JPWO2020172485A5 (https=) 2023-02-20
JP2022520997A5 JP2022520997A5 (https=) 2023-02-20

Family

ID=72144740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549213A Pending JP2022520997A (ja) 2019-02-22 2020-02-21 イミプリドンを使用する方法

Country Status (3)

Country Link
US (1) US20220143024A1 (https=)
JP (1) JP2022520997A (https=)
WO (1) WO2020172485A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521797A (ja) * 2019-02-27 2022-04-12 マデラ セラピューティクス，エルエルシー イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4337214A4 (en) * 2021-05-13 2025-01-29 Chimerix, Inc. USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMAS
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
WO2024199457A1 (zh) * 2023-03-31 2024-10-03 苏州安赛隆医药科技有限公司 并环结构化合物、其制备方法及其用途以及药物组合物及其用途
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives
WO2025250553A1 (en) * 2024-05-28 2025-12-04 Chimerix, Inc. Solid state forms of imipridone derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132661A2 (en) * 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925251B2 (en) * 2011-10-19 2018-03-27 President And Fellows Of Harvard College Treatments for Mycobacterium tuberculosis
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132661A2 (en) * 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS CHEM. BIOL., vol. 13, JPN6024005391, 2018, pages 1413 - 1425, ISSN: 0005259901 *
CANCER CELL, vol. 27, JPN6024005390, 2015, pages 864 - 876, ISSN: 0005259900 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521797A (ja) * 2019-02-27 2022-04-12 マデラ セラピューティクス，エルエルシー イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用
JP7709379B2 (ja) 2019-02-27 2025-07-16 マデラ セラピューティクス，エルエルシー イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用

Also Published As

Publication number Publication date
US20220143024A1 (en) 2022-05-12
WO2020172485A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP2022520997A (ja) イミプリドンを使用する方法
US12577208B2 (en) TEAD inhibitors and uses thereof
Trivedi et al. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells
Kerr et al. The next generation of immunotherapy for cancer: small molecules could make big waves
Ramsey et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia
Ma et al. Histone lactylation-driven B7-H3 expression promotes tumor immune evasion
RU2708032C2 (ru) ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
EP3083964B1 (en) Human mesothelin chimeric antigen receptors and uses thereof
Zong et al. PARP mediated DNA damage response, genomic stability and immune responses
McNeer et al. Acute lymphoblastic leukemia
KR20250134209A (ko) 키메라 항원 수용체에 관한 방법 및 조성물
ZA200603563B (en) Enhanced B cell cytotoxicity of CDIM binding antibody
EP1814913B1 (en) Antibody induced cell membrane wounding
JP7825465B2 (ja) Ｔｕｓｃ２免疫療法のための方法および組成物
Afolabi et al. Synergistic tumor cytolysis by NK cells in combination with a pan-HDAC inhibitor, panobinostat
WO2022265864A9 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
Zhang et al. Sodium tanshinone IIA sulfonate as a potent IDO1/TDO2 dual inhibitor enhances anti-PD1 therapy for colorectal cancer in mice
EP3365468A1 (en) Polymerase q as a target in hr-deficient cancers
Li et al. Recent advances in developing novel anti-cancer drugs targeting tumor hypoxic and acidic microenvironments
Marjoncu et al. Gilteritinib: a novel FLT3 inhibitor for relapsed/refractory acute myeloid leukemia
WO2022192372A1 (en) Methods and compositions for tusc2 combination therapy with pdk1 inhibition
WO2013043255A1 (en) Methods and compositions for the treatment of ovarian cancer
Prihoda Genetic Mutations and Targeted Therapy in Leukemia
Zarabi Preclinical evaluation of a novel anti-leukemic mechanism
Manjunath et al. Towards Targeted Therapy: Anticancer Agents Targeting Cell Organelle Mitochondria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230210

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241017